ES2897998T3 - Inhibidores de la acilsulfonamida del NaV1.7 - Google Patents

Inhibidores de la acilsulfonamida del NaV1.7 Download PDF

Info

Publication number
ES2897998T3
ES2897998T3 ES17794203T ES17794203T ES2897998T3 ES 2897998 T3 ES2897998 T3 ES 2897998T3 ES 17794203 T ES17794203 T ES 17794203T ES 17794203 T ES17794203 T ES 17794203T ES 2897998 T3 ES2897998 T3 ES 2897998T3
Authority
ES
Spain
Prior art keywords
mmol
benzenesulfonamide
chloro
alkyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17794203T
Other languages
English (en)
Spanish (es)
Inventor
Yong-Jin Wu
Jason M Guernon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2897998T3 publication Critical patent/ES2897998T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES17794203T 2016-10-27 2017-10-26 Inhibidores de la acilsulfonamida del NaV1.7 Active ES2897998T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413555P 2016-10-27 2016-10-27
PCT/US2017/058472 WO2018081384A1 (en) 2016-10-27 2017-10-26 Acyl sulfonamide nav1.7 inhibitors

Publications (1)

Publication Number Publication Date
ES2897998T3 true ES2897998T3 (es) 2022-03-03

Family

ID=60245256

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17794203T Active ES2897998T3 (es) 2016-10-27 2017-10-26 Inhibidores de la acilsulfonamida del NaV1.7

Country Status (8)

Country Link
US (1) US10836758B2 (OSRAM)
EP (1) EP3532462B1 (OSRAM)
JP (1) JP7072569B2 (OSRAM)
KR (1) KR102561076B1 (OSRAM)
CN (1) CN110088093B (OSRAM)
ES (1) ES2897998T3 (OSRAM)
MA (1) MA46615A (OSRAM)
WO (1) WO2018081384A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7022751B2 (ja) 2016-12-09 2022-02-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
SG11202011862PA (en) 2018-06-13 2020-12-30 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
WO2020117626A1 (en) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
CN111285825B (zh) * 2018-12-10 2023-02-17 中国科学院上海药物研究所 一类苯磺酰胺取代的衍生物，其制法及其用途
WO2020199683A1 (zh) * 2019-04-04 2020-10-08 上海海雁医药科技有限公司 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途
WO2020248123A1 (en) * 2019-06-11 2020-12-17 Merck Sharp & Dohme Corp. Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP4402276A1 (en) 2021-09-15 2024-07-24 Richter Gedeon Nyrt. Process to produce (1 r, 4 r)-4-substituted cyclohexane-1-amines
WO2025096637A1 (en) * 2023-10-31 2025-05-08 Xenon Pharmaceuticals Inc. Substituted aryl sulfonamides for use as sodium channel inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012015723A1 (en) * 2010-07-26 2012-02-02 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
TW201623264A (zh) * 2014-03-29 2016-07-01 魯賓有限公司 作為電位閘控鈉通道調節劑之磺胺化合物
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
GB201518888D0 (en) * 2015-10-24 2015-12-09 Smiths Medical Int Ltd Medico-surgical tubes and their manufacture
JP2019502688A (ja) 2015-12-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有するジアミノ−アルキルアミノ結合アリールスルホンアミド化合物
CN108699015A (zh) 2015-12-18 2018-10-23 默沙东公司 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物

Also Published As

Publication number Publication date
JP7072569B2 (ja) 2022-05-20
KR102561076B1 (ko) 2023-07-28
KR20190067895A (ko) 2019-06-17
CN110088093A (zh) 2019-08-02
EP3532462B1 (en) 2021-10-13
EP3532462A1 (en) 2019-09-04
WO2018081384A1 (en) 2018-05-03
CN110088093B (zh) 2023-06-13
MA46615A (fr) 2019-09-04
US10836758B2 (en) 2020-11-17
US20200048240A1 (en) 2020-02-13
JP2019536764A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
ES2897998T3 (es) Inhibidores de la acilsulfonamida del NaV1.7
AU2019204244B2 (en) Cyclopropylamines as lsd1 inhibitors
TWI789381B (zh) 雜環化合物
ES2586213T3 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
IL275058B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
JP2024530952A (ja) ｐ５３変異体を標的とする化合物
RS63201B1 (sr) Antibakterijska jedinjenja
PT2070922E (pt) Derivados de azabiciclo(3.1.0)hexano úteis como moduladores dos receptores d3 da dopamina
AU2020204341B2 (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
HU228774B1 (en) Substituted 1-oxa-2,8-diaza-spiro[4.5]dec-2-ene derivatives, process for their preparation, their use and pharmaceutical compositions containing them
CA3202330A1 (en) Compounds useful as t cell activators
ES2546430T3 (es) Nuevos compuestos de benzodioxol-piperazina
KR102667331B1 (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR20180134998A (ko) 아실 술폰아미드 NaV1.7 억제제
MX2013008420A (es) Compuestos novedosos de benzodioxol piperidina.
NZ717552A (en) Piperidine urea derivatives
CN119998264A (zh) 新双环杂环基化合物及其用途
JP2010508351A (ja) Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
AU2019229188B2 (en) Substituted cyclohexyl compounds as NOP inhibitors
CN117120443A (zh) 作为腺苷A2a受体拮抗剂的化合物及包含其的药物组合物
EP4211118A1 (en) Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
RU2820477C1 (ru) Производные 5-окса-2-азаспиро[3.4]октана в качестве агонистов m4
WO2019081939A1 (en) 2-AZABICYCLO [3.1.1] DERIVATIVES AS ANTAGONISTS OF OREXIN-1 AND OREXIN-2 RECEPTORS
EA050101B1 (ru) СОЕДИНЕНИЯ, ТАРГЕТИРУЮЩИЕ МУТАНТ р53
KR20230153959A (ko) 신규한 pim 키나아제 억제 화합물 및 이의 용도